{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:16:26Z","timestamp":1793661386680,"version":"4.5.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2011,2,13]],"date-time":"2011-02-13T00:00:00Z","timestamp":1297555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/2.0"},{"start":{"date-parts":[[2011,2,13]],"date-time":"2011-02-13T00:00:00Z","timestamp":1297555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/2.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1007\/s11239-011-0551-3","type":"journal-article","created":{"date-parts":[[2011,2,12]],"date-time":"2011-02-12T02:37:54Z","timestamp":1297478274000},"page":"478-492","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":175,"title":["Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor"],"prefix":"10.1007","volume":"31","author":[{"given":"Pancras C.","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald J. P.","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donglu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,2,13]]},"reference":[{"key":"551_CR1","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1161\/CIRCULATIONAHA.109.192666","volume":"121","author":"D Lloyd-Jones","year":"2010","unstructured":"Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G et al (2010) American Heart Association Statistics Committee and Stroke Statistics Committee. Executive summary: heart disease and stroke statistics\u20142010 update: a report from the American Heart Association. Circulation 121:948\u2013954","journal-title":"Circulation"},{"key":"551_CR2","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1185\/03007995.2010.516090","volume":"26","author":"A Ruppert","year":"2010","unstructured":"Ruppert A, Lees M, Steinle T (2010) Clinical burden of venous thromboembolism. Curr Med Res Opin 26:2465\u20132473","journal-title":"Curr Med Res Opin"},{"key":"551_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1161\/01.ATV.0000046238.23903.FC","volume":"23","author":"KG Mann","year":"2003","unstructured":"Mann KG, Butenas S, Brummel K (2003) The dynamics of thrombin formation. Arterioscler Thromb Vasc Biol 23:17\u201325","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"551_CR4","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1161\/01.ATV.16.10.1285","volume":"16","author":"CR McKenzie","year":"1996","unstructured":"McKenzie CR, Abendschein DR, Eisenberg PR (1996) Sustained inhibition of whole-blood clot procoagulant activity by inhibition of thrombus-associated factor Xa. Arterioscler Thromb Vasc Biol 16:1285\u20131291","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"551_CR5","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1055\/s-0038-1642723","volume":"74","author":"LA Harker","year":"1995","unstructured":"Harker LA, Hanson SR, Kelly AB (1995) Antithrombotic benefits and hemorrhagic risks of direct thrombin antagonists. Thromb Haemost 74:464\u2013472","journal-title":"Thromb Haemost"},{"key":"551_CR6","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1124\/jpet.102.040089","volume":"303","author":"PC Wong","year":"2002","unstructured":"Wong PC, Crain EJ, Watson CA, Zaspel AM, Wright MR, Lam PY et al (2002) Nonpeptide factor Xa inhibitors III: effects of DPC423, an orally-active pyrazole antithrombotic agent, on arterial thrombosis in rabbits. J Pharmacol Exp Ther 303:993\u20131000","journal-title":"J Pharmacol Exp Ther"},{"key":"551_CR7","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1111\/j.1538-7836.2009.03503.x","volume":"7","author":"PC Wong","year":"2009","unstructured":"Wong PC, Crain EJ, Watson CA, Xin B (2009) Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits. J Thromb Haemost 7:1313\u20131320","journal-title":"J Thromb Haemost"},{"key":"551_CR8","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0049-3848(98)00192-3","volume":"93","author":"J Hauptmann","year":"1999","unstructured":"Hauptmann J, Sturzebecher J (1999) Synthetic inhibitors of thrombin and factor Xa: from bench to bedside. Thromb Res 93:203\u2013241","journal-title":"Thromb Res"},{"key":"551_CR9","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2174\/1568026013395380","volume":"1","author":"RJ Leadley Jr","year":"2001","unstructured":"Leadley RJ Jr (2001) Coagulation factor Xa inhibition: biological background and rationale. Curr Top Med Chem 1:151\u2013159","journal-title":"Curr Top Med Chem"},{"key":"551_CR10","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1517\/14656566.5.6.1373","volume":"5","author":"AG Turpie","year":"2004","unstructured":"Turpie AG (2004) Fondaparinux: a factor Xa inhibitor for antithrombotic therapy. Expert Opin Pharmacother 5:1373\u20131384","journal-title":"Expert Opin Pharmacother"},{"issue":"6 Suppl","key":"551_CR11","doi-asserted-by":"publisher","first-page":"160S","DOI":"10.1378\/chest.08-0670","volume":"133","author":"J Ansell","year":"2008","unstructured":"Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G (2008) Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 133(6 Suppl):160S\u2013198S","journal-title":"Chest"},{"key":"551_CR12","unstructured":"FDA News Release, Oct 19, 2010. FDA approves Pradaxa to prevent stroke in people with atrial fibrillation [online]. http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm230241.htm. Accessed 22 Dec 2010"},{"key":"551_CR13","doi-asserted-by":"publisher","first-page":"5339","DOI":"10.1021\/jm070245n","volume":"50","author":"DJ Pinto","year":"2007","unstructured":"Pinto DJ, Orwat MJ, Koch S, Rossi KA, Alexander RS, Smallwood A et al (2007) Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrah ydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem 50:5339\u20135356","journal-title":"J Med Chem"},{"key":"551_CR14","doi-asserted-by":"publisher","first-page":"6243","DOI":"10.1021\/jm100146h","volume":"53","author":"DJ Pinto","year":"2010","unstructured":"Pinto DJ, Smallheer JM, Cheney DL, Knabb RM, Wexler RR (2010) Factor Xa inhibitors: next-generation antithrombotic agents. J Med Chem 53:6243\u20136274","journal-title":"J Med Chem"},{"key":"551_CR15","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1111\/j.1538-7836.2008.02939.x","volume":"6","author":"PC Wong","year":"2008","unstructured":"Wong PC, Crain EJ, Xin B, Wexler RR, Lam PY, Pinto DJ et al (2008) Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost 6:820\u2013829","journal-title":"J Thromb Haemost"},{"key":"551_CR16","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1161\/CIRCULATIONAHA.108.832139","volume":"119","author":"APPRAISE Steering Committee and Investigators","year":"2009","unstructured":"APPRAISE Steering Committee and Investigators, Becker RC, Bhatt DL, Cools F, Crea F, Dellborg M et al (2009) Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 119:2877\u20132885","journal-title":"Circulation"},{"key":"551_CR17","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1111\/j.1538-7836.2008.03054.x","volume":"6","author":"H Buller","year":"2008","unstructured":"Botticelli Investigators Writing Committee, Buller H, Deitchman D, Prins M, Segers A (2008) Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost 6:1313\u20131318","journal-title":"J Thromb Haemost"},{"key":"551_CR18","unstructured":"Connolly S, Eikelboom J, Flaker G, Kaatz S, Avezum A, Piegas L et al AVERROES: apixaban versus acetylsalicylic acid (ASA) to prevent strokes. ESC 2010 congress reports. European Society of Cardiology web site. http:\/\/www.escardio.org\/congresses\/esc-2010\/congress-reports\/Pages\/708-3-AVERROES.aspx#presenter. Accessed 6 Sept 2010"},{"key":"551_CR19","unstructured":"Frost C, Yu Z, Moore K, Nepal S, Barrett Y, Mosqueda-Garcia R et al (2007) Apixaban, an oral direct factor Xa inhibitor: multiple-dose safety, pharmacokinetics, and pharmacodynamics in healthy subjects. J Thromb Haemost 5(Suppl 2). Abstract PM664"},{"key":"551_CR20","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1111\/j.1538-7836.2007.02764.x","volume":"5","author":"MR Lassen","year":"2007","unstructured":"Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D (2007) The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 5:2368\u20132375","journal-title":"J Thromb Haemost"},{"key":"551_CR21","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1056\/NEJMoa0810773","volume":"361","author":"MR Lassen","year":"2009","unstructured":"Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ et al (2009) Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 361:594\u2013604","journal-title":"N Engl J Med"},{"key":"551_CR22","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/S0140-6736(09)62125-5","volume":"375","author":"MR Lassen","year":"2010","unstructured":"Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P et al (2010) Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 375:807\u2013815","journal-title":"Lancet"},{"key":"551_CR23","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1016\/S0960-894X(97)10081-6","volume":"7","author":"ML Quan","year":"1997","unstructured":"Quan ML, Pruitt JR, Ellis CD, Liauw AY, Galemmo RA Jr, Stouten PFW et al (1997) Bisbenzamidine isoxazoline derivatives as factor Xa inhibitors. Bioorg Med Chem Lett 7:2813\u20132818","journal-title":"Bioorg Med Chem Lett"},{"key":"551_CR24","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.1021\/jm980406a","volume":"42","author":"ML Quan","year":"1999","unstructured":"Quan ML, Ellis CD, Liauw AY, Alexander RS, Knabb RM, Lam G et al (1999) Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 2. J Med Chem 42:2760\u20132773","journal-title":"J Med Chem"},{"key":"551_CR25","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.1021\/jm980405i","volume":"42","author":"ML Quan","year":"1999","unstructured":"Quan ML, Liauw AY, Ellis CD, Pruitt JR, Carini DJ, Bostrom LL et al (1999) Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 1. J Med Chem 42:2752\u20132759","journal-title":"J Med Chem"},{"key":"551_CR26","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0022-3565(24)35299-1","volume":"292","author":"PC Wong","year":"2000","unstructured":"Wong PC, Quan ML, Crain EJ, Watson CA, Wexler RR, Knabb RM (2000) Nonpeptide factor Xa inhibitors: I. Studies with SF303 and SK549, a new class of potent antithrombotics. J Pharmacol Exp Ther 292:351\u2013357","journal-title":"J Pharmacol Exp Ther"},{"key":"551_CR27","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S0960-894X(00)00097-4","volume":"10","author":"JR Pruitt","year":"2000","unstructured":"Pruitt JR, Pinto DJ, Estrella MJ, Bostrom LL, Knabb RM, Wong PC et al (2000) Isoxazolines and isoxazoles as factor Xa inhibitors. Bioorg Med Chem Lett 10:685\u2013689","journal-title":"Bioorg Med Chem Lett"},{"key":"551_CR28","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1021\/jm000409z","volume":"44","author":"DJ Pinto","year":"2001","unstructured":"Pinto DJ, Orwat MJ, Wang S, Fevig JM, Quan ML, Amparo E et al (2001) Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-2\u2032-(methylsulfonyl)-[1,1\u2032-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem 44:566\u2013578","journal-title":"J Med Chem"},{"key":"551_CR29","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/j.1527-3466.2002.tb00188.x","volume":"20","author":"PC Wong","year":"2002","unstructured":"Wong PC, Pinto DJ, Knabb RM (2002) Nonpeptide factor Xa inhibitors: DPC423, a highly potent and orally bioavailable pyrazole antithrombotic agent. Cardiovasc Drug Rev 20:137\u2013152","journal-title":"Cardiovasc Drug Rev"},{"key":"551_CR30","first-page":"1023","volume":"41","author":"JS Barrett","year":"2001","unstructured":"Barrett JS, Davidson AF, Jiao QT, Masqueda-Garcia R, Kornhauser DM, Gangrade NK et al (2001) The effect of food, formulation, and dosing duration on the pharmacokinetics of DPC-423, a potent factor Xa inhibitor (abstract). J Clin Pharmacol 41:1023","journal-title":"J Clin Pharmacol"},{"key":"551_CR31","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1021\/jm0497949","volume":"48","author":"ML Quan","year":"2005","unstructured":"Quan ML, Lam PY, Han Q, Pinto DJ, He MY, Li R et al (2005) Discovery of 1-(3\u2032-aminobenzisoxazol-5\u2032-yl)-3-trifluoromethyl-N-[2-fluoro-4-[(2\u2032-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor. J Med Chem 48:1729\u20131744","journal-title":"J Med Chem"},{"key":"551_CR32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11239-007-0017-9","volume":"24","author":"PC Wong","year":"2007","unstructured":"Wong PC, Crain EJ, Watson CA, Wexler RR, Lam PY, Quan ML et al (2007) Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and\/or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbits. J Thromb Thrombolysis 24:43\u201351","journal-title":"J Thromb Thrombolysis"},{"key":"551_CR33","unstructured":"Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D (2003) A phase II randomized, double-blind, five-arm, parallel-group, dose-response study of a new oral directly-acting factor Xa inhibitor, razaxaban, for the prevention of deep vein thrombosis in knee replacement surgery\u2014on behalf of the razaxaban investigators. Blood (ASH Annual Meeting Abstracts) 102:111. Abstract 41"},{"key":"551_CR34","doi-asserted-by":"publisher","first-page":"4141","DOI":"10.1016\/j.bmcl.2006.02.069","volume":"16","author":"DJ Pinto","year":"2006","unstructured":"Pinto DJ, Orwat MJ, Quan ML, Han Q, Galemmo RA Jr, Amparo E et al (2006) 1-[3-Aminobenzisoxazol-5\u2032-yl]-3-trifluoromethyl-6-[2\u2032-(3-(R)-hydroxy-N-pyr rolidinyl)methyl-[1,1\u2032]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-py ridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. Bioorg Med Chem Lett 16:4141\u20134147","journal-title":"Bioorg Med Chem Lett"},{"key":"551_CR35","doi-asserted-by":"publisher","unstructured":"Luettgen JM, Knabb RM, He K, Pinto DJ, Rendina AR (2011) Apixaban inhibition of factor Xa: Microscopic rate constants and inhibition mechanism in purified protein systems and in human plasma. J Enzyme Inhib Med Chem. Posted online on 20 Dec 2010. doi:10.3109\/14756366.2010.535793","DOI":"10.3109\/14756366.2010.535793"},{"key":"551_CR36","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1538-7836.2004.01021.x","volume":"3","author":"S Krishnaswamy","year":"2005","unstructured":"Krishnaswamy S (2005) Exosite-driven substrate specificity and function in coagulation. J Thromb Haemost 3:54\u201367","journal-title":"J Thromb Haemost"},{"key":"551_CR37","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1160\/TH08-07-0486","volume":"101","author":"X Jiang","year":"2009","unstructured":"Jiang X, Crain EJ, Luettgen JM, Schumacher WA, Wong PC (2009) Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro. Thromb Haemost 101:780\u2013782","journal-title":"Thromb Haemost"},{"key":"551_CR38","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/0049-3848(95)00155-K","volume":"80","author":"T Hara","year":"1995","unstructured":"Hara T, Yokoyama A, Morishima Y, Kunitada S (1995) Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor. Thromb Res 80:99\u2013104","journal-title":"Thromb Res"},{"key":"551_CR39","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/j.1538-7836.2005.01166.x","volume":"3","author":"E Perzborn","year":"2005","unstructured":"Perzborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, Schlemmer KH et al (2005) In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939\u2014an oral, direct factor Xa inhibitor. J Thromb Haemost 3:514\u2013521","journal-title":"J Thromb Haemost"},{"key":"551_CR40","unstructured":"Luettgen J, Wang Z, Seiffert D, Rendina A, Knabb R, Ogletree M (2007) Inhibition of measured thrombin generation in human plasma by apixaban: a predictive mathematical model based on experimentally determined rate constants. J Thromb Haemost 5(Suppl 2). Abstract PT633"},{"key":"551_CR41","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1160\/TH10-02-0097","volume":"104","author":"PC Wong","year":"2010","unstructured":"Wong PC, Jiang X (2010) Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin. Thromb Haemost 104:302\u2013310","journal-title":"Thromb Haemost"},{"key":"551_CR42","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1097\/FJC.0b013e3181daded3","volume":"55","author":"WA Schumacher","year":"2010","unstructured":"Schumacher WA, Bostwick JS, Stewart AB, Steinbacher TE, Xin B, Wong PC (2010) Effect of the direct factor Xa inhibitor apixaban in rat models of thrombosis and hemostasis. J Cardiovasc Pharmacol 55:609\u2013616","journal-title":"J Cardiovasc Pharmacol"},{"key":"551_CR43","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1160\/TH08-07-0456","volume":"101","author":"PC Wong","year":"2009","unstructured":"Wong PC, Crain EJ, Watson CA, Hua J, Schumacher WA, Rehfuss R (2009) Clopidogrel versus prasugrel in rabbits. Effects on thrombosis, haemostasis, platelet function and response variability. Thromb Haemost 101:108\u2013115","journal-title":"Thromb Haemost"},{"key":"551_CR44","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1111\/j.1538-7836.2008.03092.x","volume":"6","author":"PC Wong","year":"2008","unstructured":"Wong PC, Watson CA, Crain EJ (2008) Arterial antithrombotic and bleeding time effects of apixaban, a direct factor Xa inhibitor, in combination with antiplatelet therapy in rabbits. J Thromb Haemost 6:1736\u20131741","journal-title":"J Thromb Haemost"},{"key":"551_CR45","unstructured":"Bristol Myers Squibb Press Releases, Nov 18, 2010. APPRAISE-2 study with investigational compound apixaban in acute coronary syndrome discontinued [online]. http:\/\/www.bms.com\/news\/press_releases\/pages\/default.aspx?RSSLink=http:\/\/www.businesswire.com\/news\/bms\/20101118007161\/en&t=634266370298980311. Accessed 29 Nov 2010"},{"issue":"26","key":"551_CR46","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa1006885","volume":"363","author":"MR Lassen","year":"2010","unstructured":"Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM, ADVANCE-3 Investigators (2010) Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 363(26):2487\u20132498","journal-title":"N Engl J Med"},{"key":"551_CR47","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1160\/TH10-05-0328","volume":"104","author":"YC Barrett","year":"2010","unstructured":"Barrett YC, Wang Z, Frost C, Shenker A (2010) Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 104:1263\u20131271","journal-title":"Thromb Haemost"},{"key":"551_CR48","doi-asserted-by":"crossref","unstructured":"He K, He B, Grace JE, Xin B, Zhang D, Pinto D et al (2006) Preclinical pharmacokinetics and metabolism of apixaban, a potent and selective factor Xa inhibitor. Blood (ASH Annual Meeting Abstracts) 108. Abstract 910","DOI":"10.1182\/blood.V108.11.910.910"},{"key":"551_CR49","first-page":"1132","volume":"48","author":"C Frost","year":"2008","unstructured":"Frost C, Yu Z, Nepal S, Bragat A, Moore K, Shenker A et al (2008) Apixaban, a direct factor Xa inhibitor: single-dose pharmacokinetics and pharmacodynamics of an intravenous formulation. J Clin Pharmacol 48:1132. Abstract 142","journal-title":"J Clin Pharmacol"},{"key":"551_CR50","first-page":"1124","volume":"49","author":"B Vakkalagadda","year":"2009","unstructured":"Vakkalagadda B, Frost C, Wang J, Nepal S, Schuster A, Zhang D et al (2009) Effect of rifampin on the pharmacokinetics of apixaban, an oral direct inhibitor of factor Xa. J Clin Pharamcol 49:1124. Abstract 143","journal-title":"J Clin Pharamcol"},{"key":"551_CR51","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s11239-009-0401-8","volume":"29","author":"D Zhang","year":"2010","unstructured":"Zhang D, He K, Raghavan N, Wang L, Crain EJ, He B et al (2010) Metabolism, pharmacokinetics and pharmacodynamics of the factor Xa inhibitor apixaban in rabbits. J Thromb Thrombolysis 29:70\u201380","journal-title":"J Thromb Thrombolysis"},{"key":"551_CR52","unstructured":"Frost C, Yu Z, Nepal S, Mosqueda-Garcia R, Shenker A (2007) Apixaban, an oral direct, factor Xa inhibitor: single-dose safety, pharmacokinetics and pharmacodynamics in healthy subjects. J Thromb Haemost 5(Suppl 2). Abstract P-M-665"},{"issue":"1","key":"551_CR53","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1124\/dmd.108.023143","volume":"37","author":"N Raghavan","year":"2009","unstructured":"Raghavan N, Frost CE, Yu Z, He K, Zhang H, Humphreys WG et al (2009) Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 37(1):74\u201381","journal-title":"Drug Metab Dispos"},{"key":"551_CR54","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1124\/dmd.108.025593","volume":"37","author":"L Wang","year":"2009","unstructured":"Wang L, Raghavan N, He K, Luettgen JM, Humphreys WG, Knabb RM et al (2009) Sulfation of o-demethyl apixaban: enzyme identification and species comparison. Drug Metab Dispos 37:802\u2013808","journal-title":"Drug Metab Dispos"},{"key":"551_CR55","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1124\/dmd.108.025981","volume":"37","author":"D Zhang","year":"2009","unstructured":"Zhang D, He K, Raghavan N, Wang L, Mitroka J, Maxwell BD et al (2009) Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans. Drug Metab Dispos 37:1738\u20131748","journal-title":"Drug Metab Dispos"},{"key":"551_CR56","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1124\/dmd.109.029694","volume":"38","author":"L Wang","year":"2010","unstructured":"Wang L, Zhang D, Raghavan N, Yao M, Ma L, Frost CE et al (2010) In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos 38:448\u2013458","journal-title":"Drug Metab Dispos"},{"key":"551_CR57","first-page":"1123","volume":"49","author":"C Frost","year":"2009","unstructured":"Frost C, Wang J, Nepal S, Schuster A, Zhang D, Yu Z et al (2009) Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. J Clin Pharmacol 49:1123. Abstract 139","journal-title":"J Clin Pharmacol"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-011-0551-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-011-0551-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s11239-011-0551-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-011-0551-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T15:39:52Z","timestamp":1740929992000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-011-0551-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,13]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["551"],"URL":"https:\/\/doi.org\/10.1007\/s11239-011-0551-3","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,13]]},"assertion":[{"value":"13 February 2011","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}